LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist B in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset - HMS LINCS Database

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist B in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20359)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 31 of 67
Next
>>
>
751 to 775 of 1656 records
per page:

Small Molecule	barcode	cell_count	frac_dead	corpse_count	cell_count_dead	row	column	agent	concentration	role	timepoint	replicate	cell_line	dead_count	fraction_dead	cell_count__time0	dead_count__time0	cell_count__ctrl	dead_count__ctrl	fraction_dead__ctrl	increase_fraction_dead	GRvalue
Etoposide	180622_BG_7	10565	0.0218	73	159	7	14	Etoposide	0.099799999	treatment	72	2	MCF10A-GM_4	232	0.0215	832.0	168.3	20016	537.9	0.0261	-0.00464	0.7400
Etoposide	180622_BG_7	12089	0.0184	52	172	11	16	Etoposide	0.099799999	treatment	72	2	MCF10A-GM_5	224	0.0182	832.0	168.3	20016	537.9	0.0261	-0.00793	0.7919
Etoposide	180622_BG_7	12621	0.0152	40	153	11	20	Etoposide	0.099799999	treatment	72	2	MCF10A-GM_6	193	0.0151	832.0	168.3	20016	537.9	0.0261	-0.01106	0.8088
Etoposide	180622_BG_8	12153	0.0216	58	206	3	22	Etoposide	0.099799999	treatment	72	2	MCF10A-GM_7	264	0.0213	832.0	168.3	20016	537.9	0.0261	-0.00486	0.7939
Etoposide	180622_BG_8	13450	0.0232	61	252	11	13	Etoposide	0.099799999	treatment	72	2	MCF10A-GM_8	313	0.0227	832.0	168.3	20016	537.9	0.0261	-0.00338	0.8340
Etoposide	180622_BG_8	12030	0.0265	67	254	11	17	Etoposide	0.099799999	treatment	72	2	MCF10A-GM_9	321	0.0260	832.0	168.3	20016	537.9	0.0261	-0.00014	0.7899
Etoposide	180622_BG_6	4705	0.0596	161	129	8	4	Etoposide	0.316033316	treatment	72	2	MCF10A-GM_1	290	0.0581	832.0	168.3	20016	537.9	0.0261	0.03193	0.4588
Etoposide	180622_BG_6	5287	0.0424	114	115	10	6	Etoposide	0.316033316	treatment	72	2	MCF10A-GM_2	229	0.0415	832.0	168.3	20016	537.9	0.0261	0.01539	0.4963
Etoposide	180622_BG_6	5058	0.0513	151	116	11	8	Etoposide	0.316033316	treatment	72	2	MCF10A-GM_3	267	0.0501	832.0	168.3	20016	537.9	0.0261	0.02402	0.4819
Etoposide	180622_BG_7	5478	0.0461	141	118	8	3	Etoposide	0.316033316	treatment	72	2	MCF10A-GM_4	259	0.0451	832.0	168.3	20016	537.9	0.0261	0.01902	0.5079
Etoposide	180622_BG_7	5223	0.0290	56	97	9	7	Etoposide	0.316033316	treatment	72	2	MCF10A-GM_5	153	0.0285	832.0	168.3	20016	537.9	0.0261	0.00233	0.4924
Etoposide	180622_BG_7	4896	0.0393	92	104	11	7	Etoposide	0.316033316	treatment	72	2	MCF10A-GM_6	196	0.0385	832.0	168.3	20016	537.9	0.0261	0.01237	0.4715
Etoposide	180622_BG_8	5864	0.0315	80	107	6	22	Etoposide	0.316033316	treatment	72	2	MCF10A-GM_7	187	0.0309	832.0	168.3	20016	537.9	0.0261	0.00478	0.5305
Etoposide	180622_BG_8	5843	0.0228	47	87	8	16	Etoposide	0.316033316	treatment	72	2	MCF10A-GM_8	134	0.0224	832.0	168.3	20016	537.9	0.0261	-0.00371	0.5293
Etoposide	180622_BG_8	5975	0.0301	64	118	10	11	Etoposide	0.316033316	treatment	72	2	MCF10A-GM_9	182	0.0296	832.0	168.3	20016	537.9	0.0261	0.00344	0.5367
Etoposide	180622_BG_6	1107	0.1775	144	78	3	6	Etoposide	0.997999808	treatment	72	2	MCF10A-GM_1	222	0.1670	832.0	168.3	20016	537.9	0.0261	0.14092	0.0642
Etoposide	180622_BG_6	1043	0.1540	113	65	6	17	Etoposide	0.997999808	treatment	72	2	MCF10A-GM_2	178	0.1458	832.0	168.3	20016	537.9	0.0261	0.11966	0.0505
Etoposide	180622_BG_6	1052	0.1024	52	61	6	18	Etoposide	0.997999808	treatment	72	2	MCF10A-GM_3	113	0.0970	832.0	168.3	20016	537.9	0.0261	0.07087	0.0525
Etoposide	180622_BG_7	1216	0.1376	107	75	3	8	Etoposide	0.997999808	treatment	72	2	MCF10A-GM_4	182	0.1302	832.0	168.3	20016	537.9	0.0261	0.10406	0.0862
Etoposide	180622_BG_7	1270	0.1369	118	72	7	16	Etoposide	0.997999808	treatment	72	2	MCF10A-GM_5	190	0.1301	832.0	168.3	20016	537.9	0.0261	0.10401	0.0966
Etoposide	180622_BG_7	1172	0.1656	114	99	8	5	Etoposide	0.997999808	treatment	72	2	MCF10A-GM_6	213	0.1538	832.0	168.3	20016	537.9	0.0261	0.12767	0.0775
Etoposide	180622_BG_8	1229	0.1412	102	86	3	3	Etoposide	0.997999808	treatment	72	2	MCF10A-GM_7	188	0.1327	832.0	168.3	20016	537.9	0.0261	0.10655	0.0887
Etoposide	180622_BG_8	1742	0.0793	61	82	10	12	Etoposide	0.997999808	treatment	72	2	MCF10A-GM_8	143	0.0759	832.0	168.3	20016	537.9	0.0261	0.04974	0.1747
Etoposide	180622_BG_8	1474	0.1247	114	84	11	9	Etoposide	0.997999808	treatment	72	2	MCF10A-GM_9	198	0.1184	832.0	168.3	20016	537.9	0.0261	0.09230	0.1327
Etoposide	180622_BG_6	840	0.2630	179	89	3	4	Etoposide	3.193598006	treatment	72	2	MCF10A-GM_1	268	0.2419	832.0	168.3	20016	537.9	0.0261	0.21575	0.0021

|<
<<
Previous
Page 31 of 67
Next
>>
>
751 to 775 of 1656 records
per page:

HMS LINCS Project

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist B in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20359)